Related references
Note: Only part of the references are listed.Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Michael J. Flynn et al.
HEPATOLOGY (2019)
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer
Reinhard Buttner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
David J. Pinato et al.
ONCOIMMUNOLOGY (2017)
LAG-3+tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+tumors
S. Burugu et al.
ANNALS OF ONCOLOGY (2017)
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Joel C. Sunshine et al.
CLINICAL CANCER RESEARCH (2017)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain
XH He et al.
ACTA PHARMACOLOGICA SINICA (2005)
Share Paper
